Premium
FDA approves chewable methylphenidate
Publication year - 2016
Publication title -
the brown university child and adolescent psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7567
pISSN - 1527-8395
DOI - 10.1002/cpu.30098
Subject(s) - methylphenidate , food and drug administration , attention deficit hyperactivity disorder , medicine , psychiatry , drug , pharmacology
The U.S. Food and Drug Administration on December 4 approved QuilliChew ER tablets, which Pfizer officials are calling the first and only long‐acting chewable methylphenidate treatment for attention‐deficit hyperactivity disorder (ADHD) in patients ages 6 years old and above.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom